Saturday 17 October 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
121.84
0.33
+0.27%
Follow HALO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 173.67% | 99.40% | 153.59% | 124.50% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 5 | 5 | 8 | |
| 17.86% | 14.33% | 13.81% | 27.45% | ||
ROIC |
18.13% | 15.64% | 14.31% | 35.11% | |
Return on Tangible Assets |
61.47% | 48.31% | 43.39% | 105.78% | |
Average Days of Receivables |
100.00 | 110.82 | 115.33 | 101.62 | |
Free Cash Flow per Share |
6.87 | 5.65 | 5.38 | 6.31 | |
Free Cash Flow |
806.22 | 667.65 | 644.59 | 739.68 | |
Capital Expenditures |
(12.37) | (9.76) | (6.97) | 128.68 | |
| Other line items | |||||
Cash ROIC |
31.98% | 24.89% | 27.61% | 27.23% | |
Accounts Receivable Turnover |
4.31 | 3.96 | 3.73 | 3.93 | |
Accounts Payable Turnover |
13.83 | 15.19 | 14.69 | 13.84 | |
Inventory Turnover |
1.84 | 1.62 | 1.44 | 1.21 | |
Average Days of Payables |
29.47 | 19.82 | 33.34 | 29.19 | |
Days of Inventory on Hand |
171.17 | 218.58 | 281.56 | 353.10 | |
Tax Rate |
(0.29) | (0.31) | (0.32) | (0.20) | |
Research and Development Expense of Revenue |
23.28% | 25.00% | 26.23% | 5.63% | |
Selling, General and Administrative Expense of Revenue |
14.30% | 14.76% | 14.83% | 13.86% | |
Share Based Compensation of Revenue |
3.79% | 3.81% | 3.69% | 3.74% | |
Interest Coverage |
29.41 | 26.79 | 25.87 | 41.53 | |
Operating CF/Net income |
1.98 | 1.94 | 2.06 | 1.03 | |
Depreciation/Fixed assets |
1.45 | 1.31 | 1.12 | 1.17 | |
Capex/Depreciation |
(0.10) | (0.09) | (0.08) | 1.54 | |
Revenue per Share |
14.19 | 12.77 | 11.65 | 10.60 | |
Operating CF per Share |
6.98 | 5.73 | 5.44 | 5.21 | |
Capex per Share |
(0.11) | (0.08) | (0.06) | 1.10 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | (0.10) |
Columns are period end dates